The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women

Clinical Ophthalmology

Volumn 8, Issue , 2014, Pages 1401-1407

  Browning, David J ^a   Lee, Chong ^a   Rotberg, David ^a  

^a Nose and Throat Associates   (United States)

Author keywords

Actual body weight; Algorithms; Hydroxychloroquine; Ideal body weight; Retinopathy; Toxicity

Indexed keywords

HYDROXYCHLOROQUINE;

ALGORITHM; ARTICLE; BERGHOLZ ALGORITHM; BODY HEIGHT; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REGIMEN; EYE TOXICITY; FEMALE; HUMAN; HYDROXYCHLOROQUINE RETINOPATHY; MAJOR CLINICAL STUDY; METROPOLITAN LIFE INSURANCE LARGE FRAME ALGORITHM; METROPOLITAN LIFE INSURANCE SMALL FRAME ALGORITHM; MICHAELIDES ALGORITHM; NATIONAL HEART LUNG AND BLOOD INSTITUTE TABLE ALGORITHM; OUTCOME ASSESSMENT; RETINOPATHY; RETROSPECTIVE STUDY; SCREENING TEST; WALVICK ALGORITHM; WOLFE ALGORITHM;

EID: 84904991520     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S66531     Document Type: Article

References (45)

1. Payne JF, Hubbard GB III, Aaberg TM Sr, Yan J. Clinical characteristics of hydroxychloroquine retinopathy. Br J Ophthalmol. 2011;95(2): 245-250.
2. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62(6): 775-784.
3. Levy GD, Munz SJ, Paschal J, Cohen HB, Prince KJ, Peterson T. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997;40(8): 1482-1486.
4. Browning DJ, Hydroxychloroquine and Chloroquine Retinopathy: Screening for Drug Toxicity. Am J Ophthalmol. 2002;133(5):649-656.
5. Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol. 2012;130(4):461-469.
6. Browning DJ. Impact of the revised American academy of ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;155(3):418-428.
7. Walvick MD, Walvick MP, Tongson E, Ngo CH. Hydroxychloroquine: lean body weight dosing. Ophthalmology. 2011;118(10):2100.
8. Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011;129(1):30-39.
9. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med. 1983;75(1A):40-45.
10. Browning DJ. Reply to Defining Ideal Body Weight. Am J Ophthalmol. 2002;134(6):935-936.
11. Bernstein HN. Ocular safety of hydroxychloroquine sulfate (Plaquenil). South Med J. 1992;85(3):274-279.
12. Pai MP, Paloucek FP. The origin of the "Ideal" body weight equations. Ann Pharmacother. 2000;34(9):1066-1069.
13. Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006;12(4):294-304.
14. Sundelin SP, Terman A. Different effects of chloroquine and hydroxychloroquine on lysosomal function in cultured retinal pigment epithelial cells. APMIS. 2002;110(6):481-489.
15. Johnson MW, Vine AK. Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol. 1987;104(2): 139-144.
16. Bergholz R, Schroeter J, Ruther K. Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. Br J Ophthalmol. 2010;94(12):1637-1642.
17. Nowaczyk P, Murawa D, Polom K, et al. Analysis of sentinel lymph node biopsy results in colon cancer in regard of the anthropometric features of the population and body composition assessment formulas. Langenbecks Arch Surg. 2012;397(5):779-786.
18. Shah B, Sucher K, Hollenbeck CB. Comparison of ideal body weight equations and published height-weight tables with body mass index tables for healthy adults in the United States. Nutr Clin Pract. 2006; 21(3):312-319.
19. Schwartz SG, Mieler WF. Retinal and Choroidal Manifestations of Systemic Medications. In: Arevalo JF, editor. Retinal and Choroidal Manifestations of Selected Systemic Diseases. New York: Springer; 2013:479-492.
20. Fung AE, Samy CN, Rosenfeld PJ. Optical coherence tomography findings in hydroxychloroquine and chloroquine-associated maculopathy. Retinal Cases and Brief Reports. 2007;1(3):128-130.
21. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2002;109(7):1377-1382.
22. Stepien KE, Han DP, Schell J, Godara P, Rha J, Carroll J. Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss. Trans Am Ophthalmol Soc. 2009;107:28-34.
23. Elder M, Rahman AM, McLay J. Early paracentral visual field loss in patients taking hydroxychloroquine. Arch Ophthalmol. 2006; 124(12):1729-1733.
24. Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine - a reappraisal. Ophthalmology. 2003;110(7):1321-1326.
25. Mavrikakis M, Papazoglou S, Sfikakis PP, Vaiopoulos G, Rougas K. Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis. 1996;55(3):187-189.
26. Anderson C, Blaha GR, Marx JL. Humphrey visual field findings in hydroxychloroquine toxicity. Eye (Lond). 2011;25(12):1535-1545.
27. Thorne JE, Maguire AM. Retinopathy after long term, standard doses of hydroxychloroquine. Br J Ophthalmol. 1999;83(10): 1201-1202.
28. Teoh SC, Lim J, Koh A, Lim T, Fu E. Abnormalities on the multifocal electroretinogram may precede clinical signs of hydroxychloroquine retinotoxicity. Eye (Lond). 2006;20(1):129-132.
29. Anderson C, Pahk P, Blaha GR, et al. Preferential hyperacuity perimetry to detect hydroxychloroquine retinal toxicity. Retina. 2009;29(8): 1188-1192.
30. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity despite normal dose therapy. Ann Ophthalmol. 1993;25(10):385-388.
31. Bienfang D, Coblyn JS, Liang MH, Corzillius M. Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol. 2000;27(11):2703-2706.
32. Warner AE. Early hydroxychloroquine macular toxicity. Arthritis Rheum. 2001;44(8):1959-1961.
33. Weiner A, Sandberg MA, Gaudio AR, Kini MM, Berson EL. Hydroxychloroquine retinopathy. Am J Ophthalmol. 1991;112(5): 528-534.
34. Kellner S, Weinitz S, Kellner U. Spectral domain optical coherence tomography detects early stages of chloroquine retinopathy similar to multifocal electroretinography, fundus autofluorescence and near-infrared autofluorescence. Br J Ophthalmol. 2009;93(11): 1444-1447.
35. Kellner U, Renner AB, Tillack H. Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci. 2006;47(8):3531-3538.
36. Chen E, Brown DM, Benz MS, et al. Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign). Clin Ophthalmol. 2010;4: 1151-1158.
37. Rodriguez-Padilla JA, Hedges TR III, Monson B, et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol. 2007;125(6):775-780.
38. Kelmenson AT, Brar VS, Murthy RK, Chalam KV. Fundus autofluorescence and spectral domain optical coherence tomography in early detection of Plaquenil maculopathy. Eur J Ophthalmology. 2010;20(4): 785-788.
39. Reed H, Karlinsky W. Delayed onset of chloroquine retinopathy. Can Med Assoc J. 1967;97(23):1408-1411.
40. Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415-422.
41. Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med. 1983;75(1A): 25-34.
42. McDowell MA, Fryar CD, Ogden CL, Flegal KM. National Health Statistics Reports. Anthropometric reference data for children and adults: United States 2003-2006; 2008. Available from: http://www.cdc.gov/nchs/data/nhsr/nhsr010.pdf. Accessed June 25, 2014.
43. Marmor MF. Efficient and effective screening for hydroxychloroquine toxicity. Am J Ophthalmol. 2013;155(3):413-414.
44. Browning DJ. Reply to Impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;156(2):410-411.
45. Browning DJ. Hydroxychloroquine and Chloroquine Retinopathy. First edition. New York, Springer; 2014